查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951921

寡核苷酸合成市場分析及預測（至2035年）：類型、產品類型、服務、技術、應用、形式、最終用戶、製程、功能、階段

Oligonucleotide Synthesis Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Form, End User, Process, Functionality, Stage
出版日期: | 出版商: Global Insight Services | 英文 302 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

寡核苷酸合成市場預計將從2024年的62億美元成長到2034年的154億美元，複合年成長率約為10.2%。寡核苷酸合成市場涵蓋短鏈DNA或RNA分子的生產，這些分子在基因研究、診斷和治療中發揮關鍵作用。該市場的成長動力主要來自合成生物學、個人化醫療的進步以及對核酸治療方法日益成長的需求。為了滿足研究和臨床應用中對高品質寡核苷酸日益成長的需求，合成技術的創新性、可擴展性和成本效益是關鍵所在。

寡核苷酸合成市場正經歷強勁成長，這主要得益於寡核苷酸在研究和治療領域應用的不斷拓展。以細分市場來看，合成寡核苷酸細分市場由於其在診斷和治療應用中的重要作用，呈現最高的成長率。針對特定研究需求量身訂做的寡核苷酸需求顯著成長，反映出其在個人化醫療中的重要性。耗材細分市場（包括試劑和酶，它們是高效合成過程的必需品）的成長率排名第二。服務細分市場（包括契約製造和定序服務）也因生技公司外包趨勢而備受關注。自動化合成儀因其精準性和擴充性而變得不可或缺，進一步增強了市場動態。此外，對基於RNA的療法的日益關注以及新型合成技術的開發是關鍵促進因素，為市場參與企業創造了盈利的機會。預計研發投入和策略聯盟將進一步推動市場擴張和創新。

市場區隔
類型 客製化和預製寡核苷酸
產品 合成寡核苷酸、試劑和設備
服務 客製合成、寡核苷酸純化和寡核苷酸修飾
科技 固相合成、液相合成、酵素合成
目的 研究、治療、診斷、基因合成
形式 液態凍乾產品
最終用戶 學術研究機構、製藥公司、生技公司、診斷實驗室
過程 DNA合成，RNA合成
功能 反義寡核苷酸、siRNA、miRNA
步 臨床前、臨床、商業化

寡核苷酸合成市場正經歷市場佔有率的動態變化，這主要受競爭性定價策略和創新產品推出的推動。各公司正利用最尖端科技來豐富產品線，並吸引來自不同產業的多元化客戶群。對客製化寡核苷酸的需求正在迅速成長，進一步加劇了主要企業之間的競爭。這種競爭環境促進了策略聯盟和合作，使公司能夠擴展產品系列併鞏固市場地位。從競爭標竿分析的角度來看，主要參與者不斷評估其市場地位，以最佳化其策略舉措。監管影響至關重要，嚴格的指導方針影響產品開發和市場准入。嚴格的合規標準正在重塑市場格局，尤其是在北美和歐洲等法規結構更嚴格的地區。各公司正在加大研發投入，以應對這些監管挑戰，並確保產品的有效性和安全性。這種策略重點對於在競爭激烈的環境中實現持續成長至關重要。

主要趨勢和促進因素：

受個人化醫療和生物技術進步的推動，寡核苷酸合成市場正經歷強勁成長。關鍵趨勢包括對客製化寡核苷酸的需求不斷成長，這些寡核苷酸對於診斷、治療和研究等應用至關重要。基因編輯技術（尤其是CRISPR）的興起顯著促進了市場發展，因為研究人員和企業都在尋求精準高效的合成技術。此外，合成生物學的擴展也推動了對高品質寡核苷酸的需求。基因體學和蛋白質體學研究投入的增加也支撐了這個趨勢。醫療產業轉型為精準醫療也是一個關鍵的促進因素，而精準醫療高度依賴寡核苷酸為基礎的治療方法。此外，遺傳性感染疾病的日益普及也推動了對創新寡核苷酸解決方案的需求。新興市場醫療基礎設施的不斷改進正在加速推進先進生物技術的應用，這帶來了許多機會。能夠提供經濟高效且擴充性的合成解決方案的公司將獲得競爭優勢。此外，將自動化和人工智慧融入合成過程，提高了效率並節省了成本，有可能進一步推動這個充滿活力的市場的成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 客製化寡核苷酸
    • 預製寡核苷酸
  • 市場規模及預測：依產品分類
    • 合成寡核苷酸
    • 試劑
    • 裝置
  • 市場規模及預測：依服務分類
    • 客製合成
    • 寡核苷酸純化
    • 寡核苷酸修飾
  • 市場規模及預測：依技術分類
    • 固相合成
    • 溶液相合成
    • 酵素合成
  • 市場規模及預測：依應用領域分類
    • 研究
    • 治療藥物
    • 診斷
    • 基因合成
  • 市場規模及預測：依類型
    • 液體
    • 凍乾產品
  • 市場規模及預測：依最終用戶分類
    • 學術研究機構
    • 製藥公司
    • 生技公司
    • 診斷檢查室
  • 市場規模及預測：依製程分類
    • DNA合成
    • RNA合成
  • 市場規模及預測：依功能分類
    • 反義寡核苷酸
    • siRNA
    • 微型RNA
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 臨床
    • 商業的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Integrated DNA Technologies
  • Eurofins Genomics
  • LGC Biosearch Technologies
  • Gen Script Biotech
  • Twist Bioscience
  • Bio-Synthesis
  • Sigma-Aldrich
  • Biomers
  • ATDBio
  • Tri Link Bio Technologies
  • Gene Link
  • Bioneer
  • LGC Axolabs
  • Alnylam Pharmaceuticals
  • Chem Genes
  • Glen Research
  • Kaneka Eurogentec
  • Nitto Denko Avecia
  • Synbio Technologies
  • Base Pair Biotechnologies

第9章：關於我們

簡介目錄
Product Code: GIS20211

Oligonucleotide Synthesis Market is anticipated to expand from $6.2 billion in 2024 to $15.4 billion by 2034, growing at a CAGR of approximately 10.2%. The Oligonucleotide Synthesis Market encompasses the production of short DNA or RNA molecules, pivotal in genetic research, diagnostics, and therapeutics. This market is driven by advancements in synthetic biology, personalized medicine, and increased demand for nucleic acid-based therapies. Key focuses include innovation in synthesis techniques, scalability, and cost-effectiveness to meet the rising need for high-quality oligonucleotides in research and clinical applications.

The Oligonucleotide Synthesis Market is experiencing robust growth, propelled by the increasing application of oligonucleotides in research and therapeutics. Among the segments, the synthesized oligonucleotides segment is the top performer, driven by its critical role in diagnostics and therapeutic applications. Custom oligonucleotides, tailored for specific research needs, are witnessing substantial demand, reflecting their significance in personalized medicine. The consumables sub-segment, encompassing reagents and enzymes, is the second-highest performer, essential for efficient synthesis processes. The services segment, including contract manufacturing and sequencing services, is also gaining traction due to the outsourcing trend among biotech firms. Automated synthesizers are becoming indispensable, offering precision and scalability, thus enhancing market dynamics. Furthermore, the growing focus on RNA-based therapeutics and the development of novel synthesis technologies are key drivers, presenting lucrative opportunities for market participants. Investments in R&D and strategic collaborations are expected to further propel market expansion and innovation.

Market Segmentation
TypeCustom Oligonucleotides, Pre-designed Oligonucleotides
ProductSynthesized Oligonucleotides, Reagents, Equipment
ServicesCustom Synthesis, Oligo Purification, Oligo Modification
TechnologySolid-phase Synthesis, Solution-phase Synthesis, Enzymatic Synthesis
ApplicationResearch, Therapeutics, Diagnostics, Gene Synthesis
FormLiquid, Lyophilized
End UserAcademic Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Diagnostic Laboratories
ProcessDNA Synthesis, RNA Synthesis
FunctionalityAntisense Oligonucleotides, siRNA, miRNA
StagePreclinical, Clinical, Commercial

The Oligonucleotide Synthesis Market is experiencing dynamic shifts in market share, driven by competitive pricing strategies and the introduction of innovative products. Companies are leveraging cutting-edge technologies to enhance product offerings, thereby attracting a diverse clientele across various sectors. The market is witnessing a surge in demand for custom oligonucleotides, which is further fueling competition among key players. This competitive environment is fostering strategic alliances and collaborations, enabling firms to expand their product portfolios and enhance their market presence. In terms of competition benchmarking, major players are continually assessing their market positions to optimize their strategic initiatives. Regulatory influences play a pivotal role, with stringent guidelines impacting product development and market entry. The market landscape is shaped by rigorous compliance standards, particularly in regions like North America and Europe, where regulatory frameworks are more stringent. Companies are investing in research and development to navigate these regulatory challenges, ensuring product efficacy and safety. This strategic focus is essential for sustaining growth in a highly competitive environment.

Geographical Overview:

The Oligonucleotide Synthesis Market is witnessing remarkable growth across various regions, each characterized by unique dynamics. North America leads, driven by substantial investments in biotechnology and pharmaceutical research. The presence of major biotech firms and research institutions further accelerates market expansion. Europe follows closely, with a strong emphasis on innovative healthcare solutions and government support for biotechnology. The region's robust regulatory framework enhances market stability and growth prospects. In Asia Pacific, rapid advancements in genomics and personalized medicine are propelling market growth. Countries like China and India are emerging as key players, fueled by increasing investments in research and development. Latin America and the Middle East & Africa present burgeoning opportunities. Latin America is experiencing a surge in biotech startups and collaborations, while the Middle East & Africa are investing in healthcare infrastructure to support oligonucleotide synthesis. These regions are recognizing the potential of oligonucleotide technologies in advancing medical research and therapeutic applications.

The global oligonucleotide synthesis market is navigating complex challenges shaped by tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, key players in biotechnology, are adapting to trade tensions by enhancing domestic capabilities and forging strategic alliances. China is intensifying its focus on self-reliance in oligonucleotide production, driven by export limitations and geopolitical pressures. Taiwan continues to be a pivotal supplier, yet remains vulnerable to regional conflicts. The parent market is experiencing robust growth, propelled by advancements in personalized medicine and genetic research. By 2035, the market is anticipated to evolve through strategic diversification and technological innovation. Middle East conflicts contribute to supply chain disruptions and volatile energy prices, indirectly influencing production costs and market stability.

Key Trends and Drivers:

The oligonucleotide synthesis market is experiencing robust growth, driven by advancements in personalized medicine and biotechnology. Key trends include the increasing demand for custom oligonucleotides, which are essential in applications such as diagnostics, therapeutics, and research. The rise of gene editing technologies, particularly CRISPR, is significantly boosting the market as researchers and companies seek precise and efficient synthesis techniques. Moreover, the expansion of synthetic biology is fueling the need for high-quality oligonucleotides. This trend is supported by the growing investments in genomics and proteomics research. The healthcare industry's shift towards precision medicine is another crucial driver, as it relies heavily on oligonucleotide-based therapies. Additionally, the increasing prevalence of genetic disorders and infectious diseases is propelling the demand for innovative oligonucleotide solutions. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and the adoption of advanced biotechnologies is accelerating. Companies that provide cost-effective and scalable synthesis solutions stand to gain a competitive edge. Furthermore, the integration of automation and artificial intelligence in synthesis processes is poised to enhance efficiency and reduce costs, offering further growth potential in this dynamic market.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Custom Oligonucleotides
    • 4.1.2 Pre-designed Oligonucleotides
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Synthesized Oligonucleotides
    • 4.2.2 Reagents
    • 4.2.3 Equipment
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Custom Synthesis
    • 4.3.2 Oligo Purification
    • 4.3.3 Oligo Modification
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Solid-phase Synthesis
    • 4.4.2 Solution-phase Synthesis
    • 4.4.3 Enzymatic Synthesis
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Research
    • 4.5.2 Therapeutics
    • 4.5.3 Diagnostics
    • 4.5.4 Gene Synthesis
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Liquid
    • 4.6.2 Lyophilized
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Academic Research Institutes
    • 4.7.2 Pharmaceutical Companies
    • 4.7.3 Biotechnology Companies
    • 4.7.4 Diagnostic Laboratories
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 DNA Synthesis
    • 4.8.2 RNA Synthesis
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Antisense Oligonucleotides
    • 4.9.2 siRNA
    • 4.9.3 miRNA
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Preclinical
    • 4.10.2 Clinical
    • 4.10.3 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Form
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Functionality
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Form
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Functionality
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Form
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Functionality
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Form
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Functionality
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Form
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Functionality
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Form
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Functionality
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Form
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Functionality
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Form
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Functionality
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Form
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Functionality
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Form
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Functionality
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Form
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Functionality
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Form
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Functionality
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Form
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Functionality
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Form
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Functionality
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Form
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Functionality
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Form
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Functionality
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Form
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Functionality
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Form
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Functionality
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Form
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Functionality
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Form
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Functionality
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Form
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Functionality
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Form
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Functionality
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Form
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Functionality
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Form
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Functionality
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Integrated DNA Technologies
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Eurofins Genomics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 LGC Biosearch Technologies
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Gen Script Biotech
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Twist Bioscience
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Bio- Synthesis
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Sigma- Aldrich
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Biomers
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 ATDBio
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Tri Link Bio Technologies
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Gene Link
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bioneer
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 LGC Axolabs
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Alnylam Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Chem Genes
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Glen Research
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Kaneka Eurogentec
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Nitto Denko Avecia
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Synbio Technologies
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Base Pair Biotechnologies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us